ATE527022T1 - Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie - Google Patents

Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie

Info

Publication number
ATE527022T1
ATE527022T1 AT98310510T AT98310510T ATE527022T1 AT E527022 T1 ATE527022 T1 AT E527022T1 AT 98310510 T AT98310510 T AT 98310510T AT 98310510 T AT98310510 T AT 98310510T AT E527022 T1 ATE527022 T1 AT E527022T1
Authority
AT
Austria
Prior art keywords
cachexia
cyclooxygenase
tumors
tumor
inhibitors
Prior art date
Application number
AT98310510T
Other languages
English (en)
Inventor
Shinichi Kurakata
Masaharu Hanai
Saori Kanai
Tomio Kimura
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ATE527022T1 publication Critical patent/ATE527022T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47G—HOUSEHOLD OR TABLE EQUIPMENT
    • A47G7/00—Flower holders or the like
    • A47G7/02—Devices for supporting flower-pots or cut flowers
    • A47G7/04—Flower tables; Stands or hangers, e.g. baskets, for flowers
    • A47G7/044—Hanging flower-pot holders, e.g. mounted on walls, balcony fences or the like
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G5/00—Floral handling
    • A01G5/04—Mountings for wreaths, or the like; Racks or holders for flowers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
    • G09F23/00—Advertising on or in specific articles, e.g. ashtrays, letter-boxes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98310510T 1997-12-24 1998-12-21 Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie ATE527022T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP35449997 1997-12-24
JP1530698 1998-01-28
JP20490798 1998-07-21
JP26944498 1998-09-24

Publications (1)

Publication Number Publication Date
ATE527022T1 true ATE527022T1 (de) 2011-10-15

Family

ID=27456356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98310510T ATE527022T1 (de) 1997-12-24 1998-12-21 Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie

Country Status (21)

Country Link
US (3) US6887893B1 (de)
EP (1) EP0927555B1 (de)
KR (2) KR100432926B1 (de)
CN (1) CN1149990C (de)
AR (1) AR012272A1 (de)
AT (1) ATE527022T1 (de)
AU (1) AU745865B2 (de)
BR (1) BR9805544C1 (de)
CA (1) CA2257010C (de)
CZ (1) CZ299060B6 (de)
DK (1) DK0927555T3 (de)
ES (1) ES2372921T3 (de)
HU (1) HU227126B1 (de)
ID (1) ID21529A (de)
IL (3) IL127664A (de)
NO (2) NO320632B1 (de)
NZ (1) NZ333399A (de)
PL (1) PL193093B1 (de)
SA (1) SA99191102B1 (de)
TR (1) TR199802676A3 (de)
TW (1) TW562675B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CA2356929A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
EP1189628A1 (de) * 1999-06-24 2002-03-27 Pharmacia Corporation Kombination von tumornekrosefaktor (tnf) antagonisten und von cox-2 inhibitoren für die behandlung der entzündung
JP2003531202A (ja) * 2000-04-25 2003-10-21 ファルマシア・コーポレーション ３，４−ジ（カルボシクリルまたはヘテロシクリル）チオフェンの位置選択的合成
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2003020268A1 (en) * 2001-08-31 2003-03-13 Washington University Method for the treatment and prevention of cachexia
ES2295428T3 (es) * 2001-10-25 2008-04-16 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2.
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080098491A1 (en) * 2006-10-19 2008-04-24 Zoltan Laboratories Llc Mouse models to study cachexia
AU2008242720A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2205075A4 (de) * 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc Therapien zur behandlung von krebs anhand von kombinationen aus cox-2-hemmern und aromatasehemmern oder kombinationen aus cox-2-hemmern und östrogenrezeptorantagonisten
WO2009042618A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
JP2010540459A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
EP2224932A4 (de) * 2007-11-28 2011-09-14 Tragara Pharmaceuticals Inc Krebsbehandlung mit cox-2-inhibitor und antimetaboliten-kombinationen
US20110301209A1 (en) * 2007-11-28 2011-12-08 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2365752B1 (de) 2008-10-29 2014-09-24 Deciphera Pharmaceuticals, Llc Cyclopropanamide und analoge mit antikrebs-eigenschaften und antiproliferativen eigenschaften
EP2284154A1 (de) 2009-07-29 2011-02-16 Argon Pharma S.L. Antitumorigene 1,2-Diphenylpyrrolverbindungen und deren Herstellungsverfahren
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
EP3938363A1 (de) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Festkörperformen von ripretinib
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962119A (en) * 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
JPH05503919A (ja) 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
US5504107A (en) 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
US5208018A (en) 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
EP0565582A4 (de) 1990-12-13 1995-01-11 Smithkline Beecham Corp Cytokinin-suppresoren als neue entzündungshemmende medikamente.
IE914327A1 (en) 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
ATE160345T1 (de) 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JP3681388B2 (ja) 1993-07-13 2005-08-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗アレルギー性イミダゾアゼピン
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
RU2139281C1 (ru) 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
CN1143365A (zh) 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
JP3302178B2 (ja) 1994-06-22 2002-07-15 日本クラウンコルク株式会社 合成樹脂製容器蓋
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5593119A (en) * 1995-01-12 1997-01-14 At&T Global Information Solutions Company Apparatus and method for mounting a terminal
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
RO119946B1 (ro) 1995-02-13 2005-06-30 G.D. Searle & Co. Derivaţi de izoxazol, utilizaţi pentru tratamentul inflamaţiilor
JPH11509835A (ja) 1995-05-19 1999-08-31 ジー．ディー．サール アンド カンパニー 炎症を治療するための置換オキサゾール
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2180624C (en) 1995-07-12 2006-12-12 Cheuk Kun Lau Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ATE346849T1 (de) 1996-01-26 2006-12-15 Searle Llc Ein verfahren zur herstellung von 4- 2-(aryl oder heterocyclo)-1h-imidazol-1-ylöbenzolsulfonamide
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
BR9711151A (pt) * 1996-08-14 1999-08-17 Searle & Co Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
EP1977749A1 (de) 1996-10-15 2008-10-08 G.D. Searle LLC Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
AU730211B2 (en) 1996-11-19 2001-03-01 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
CA2273836A1 (en) 1996-12-10 1998-06-18 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
EP0863134A1 (de) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)-2-cyclopenten-1-on zur Verwendung als Inhibitor der Cyclooxygenase-2
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Also Published As

Publication number Publication date
TW562675B (en) 2003-11-21
CZ425898A3 (cs) 1999-07-14
IL143921A (en) 2003-11-23
PL193093B1 (pl) 2007-01-31
IL127664A (en) 2003-04-10
KR100483244B1 (ko) 2005-04-15
NO317568B1 (no) 2004-11-15
US7745481B2 (en) 2010-06-29
NO986089D0 (no) 1998-12-23
CN1149990C (zh) 2004-05-19
HUP9803018A2 (hu) 1999-10-28
US6887893B1 (en) 2005-05-03
CN1230407A (zh) 1999-10-06
HUP9803018A3 (en) 2000-09-28
HU9803018D0 (en) 1999-02-01
PL330496A1 (en) 1999-07-05
NO320632B1 (no) 2006-01-02
NO20040145L (no) 1999-06-25
SA99191102B1 (ar) 2006-10-11
CA2257010A1 (en) 1999-06-24
AU745865B2 (en) 2002-04-11
AU9822598A (en) 1999-07-15
BR9805544A (pt) 2000-03-28
HK1020261A1 (en) 2000-04-07
EP0927555A1 (de) 1999-07-07
IL127664A0 (en) 1999-10-28
NZ333399A (en) 2000-05-26
ES2372921T3 (es) 2012-01-27
IL143921A0 (en) 2002-04-21
EP0927555B1 (de) 2011-10-05
CZ299060B6 (cs) 2008-04-16
KR100432926B1 (ko) 2004-09-08
US20050014814A1 (en) 2005-01-20
KR20040025927A (ko) 2004-03-26
HU227126B1 (en) 2010-07-28
CA2257010C (en) 2009-02-17
TR199802676A2 (xx) 1999-11-22
US20050004109A1 (en) 2005-01-06
TR199802676A3 (tr) 1999-11-22
ID21529A (id) 1999-06-24
KR19990063439A (ko) 1999-07-26
DK0927555T3 (da) 2012-01-23
BR9805544C1 (pt) 2000-06-06
NO986089L (no) 1999-06-25
AR012272A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE226071T1 (de) Antikonvulsive derivate zur behandlung von neuropathischem schmerz
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties